Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cocrystal Pharma, Inc. (COCP : NSDQ)

• Company Description    Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HepC. Phase 1b studies in HepC infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 48% of the Company. Number of Employees: 11

• Price / Volume Information    Yesterday's Closing Price: $1.57 Daily Weekly Monthly 20 Day Moving Average: 15,354 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 2.07 52 Week High: $3.26 52 Week Low: $1.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.95% -1.87% 12 Week 19.85% 0.81% Year To Date -22.28% -27.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 19805 N. CREEK PARKWAY - BOTHELL,WA 98011 USA ph: 877-262-7123 fax: - jcain@allianceadvisors.com http://www.cocrystalpharma.com

• General Corporate Information    Officers Sam Lee - President and Co-Chief Executive Officer Roger Kornberg - Chairman James Martin - Chief Financial Officer and Co-Chief Executive Off Phillip Frost - Director Fred Hassan - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 19188J409 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: Most Recent Split Date: 10.00 (0.08:1) Beta: 2.07 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.29 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.19 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 41.03% vs. Previous Quarter: 28.12% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -135.12 12/31/24 - -112.56 ROA 06/30/25 - - 03/31/25 - -102.38 12/31/24 - -89.99 Current Ratio 06/30/25 - - 03/31/25 - 4.57 12/31/24 - 4.77 Quick Ratio 06/30/25 - - 03/31/25 - 4.57 12/31/24 - 4.77 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.72 12/31/24 - 0.94 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©